Celldex Announces Upcoming Late Breaking Oral Presentation Of 52-Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At EADV Congress 2024
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics announced that their Phase 2 study results for barzolvolimab in treating chronic spontaneous urticaria will be presented at the EADV Congress 2024.
September 16, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Celldex Therapeutics will present 52-week results from their Phase 2 study of barzolvolimab for chronic spontaneous urticaria at the EADV Congress 2024. This could indicate positive progress in their drug development pipeline.
The acceptance of Celldex's study results for presentation at a major congress suggests significant progress in their drug development, which is likely to positively impact investor sentiment and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100